SCHEMBL10247869

SCHEMBL10247869

O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CCN(CC(=O)O)C(=O)O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.71
BLM P54132 2/20 0.71
PMP22 Q01453 2/20 0.71
KDM4E B2RXH2 2/20 0.71
ALOX15 P16050 2/20 0.71
LMNA P02545 1/20 0.71
CHRM2 P08172 1/20 0.71
ADRA2A P08913 1/20 0.71
TSHR P16473 1/20 0.71
DRD1 P21728 1/20 0.71
SLC6A2 P23975 1/20 0.71
SLC6A4 P31645 1/20 0.71
CYP2C19 P33261 1/20 0.71
ADRA1A P35348 1/20 0.71
DRD3 P35462 1/20 0.71
SLC6A3 Q01959 1/20 0.71
HRH3 Q9Y5N1 1/20 0.71
EYA2 O00167 1/20 0.67
APP P05067 1/20 0.67
ACE P12821 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15083253 0.98 TDP1 (0.70) TDP1BLMPMP22KDM4EALOX15
SCHEMBL13863255 0.90 TDP1 (0.58) TDP1BLMPMP22KDM4EALOX15
Pentetic Acid SCHEMBL10564326 0.84 TDP1 (1.00) TDP1BLMPMP22KDM4EALOX15
Pentetic Acid SCHEMBL17138 0.84 TDP1 (1.00) TDP1BLMPMP22KDM4EALOX15
Pentetic Acid SCHEMBL2468143 0.84 TDP1 (1.00) TDP1BLMPMP22KDM4EALOX15
Pentetic Acid SCHEMBL786105 0.84 TDP1 (1.00) TDP1BLMPMP22KDM4EALOX15
SCHEMBL8866720 0.84 TDP1 (1.00) TDP1BLMPMP22KDM4EALOX15
SCHEMBL137691 0.84 TDP1 (1.00) TDP1BLMPMP22KDM4EALOX15
Pentetic Acid SCHEMBL8647927 0.82 TDP1 (0.94) TDP1BLMPMP22KDM4EALOX15
Pentetic Acid SCHEMBL9130818 0.82 TDP1 (0.94) TDP1BLMPMP22KDM4EALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130136691-A1 GASTRIN RELEASING PEPTIDE COMPOUNDS BRACCO IMAGING S.P.A. (IT) 2013-05-30 US disclosed
US-20130136691-A1 GASTRIN RELEASING PEPTIDE COMPOUNDS BRACCO IMAGING S.P.A. (IT) 2013-05-30 US disclosed
US-8444954-B2 Gastrin releasing peptide compounds BRACCO IMAGING S.P.A. (IT) 2013-05-21 US disclosed
US-8444954-B2 Gastrin releasing peptide compounds BRACCO IMAGING S.P.A. (IT) 2013-05-21 US disclosed
US-8420053-B2 Gastrin releasing peptide compounds BRACCO IMAGING S.P.A. (IT) 2013-04-16 US disclosed
US-8420053-B2 Gastrin releasing peptide compounds BRACCO IMAGING S.P.A. (IT) 2013-04-16 US disclosed
US-8420050-B2 Gastrin releasing peptide compounds BRACCO IMAGING S.P.A. (IT) 2013-04-16 US disclosed
US-8420050-B2 Gastrin releasing peptide compounds BRACCO IMAGING S.P.A. (IT) 2013-04-16 US disclosed
US-8414864-B2 Bombesin capable of complexing with metal ions, radionuclides, or optical labels; radiotherapy BRACCO IMAGING S.P.A. (IT) 2013-04-09 US disclosed
US-8414864-B2 Bombesin capable of complexing with metal ions, radionuclides, or optical labels; radiotherapy BRACCO IMAGING S.P.A. (IT) 2013-04-09 US disclosed
EP-1583564-B1 IMPROVED LINKERS FOR RADIOPHARMACEUTICAL COMPOUNDS BRACCO IMAGING SPA (IT) 2009-07-01 EP disclosed
US-20080247946-A1 Bombesin capable of complexing with metal ions, radionuclides, or optical labels; radiotherapy BRACCO IMAGING S.P.A. (IT) 2008-10-09 US disclosed
US-20080247946-A1 Bombesin capable of complexing with metal ions, radionuclides, or optical labels; radiotherapy BRACCO IMAGING S.P.A. (IT) 2008-10-09 US disclosed
US-20080008649-A1 Gastrin Releasing Peptide Compounds BRACCO IMAGING S.P.A. (IT) 2008-01-10 US disclosed
US-20080008649-A1 Gastrin Releasing Peptide Compounds BRACCO IMAGING S.P.A. (IT) 2008-01-10 US disclosed
US-20070231257-A1 Radiodiagnosis, radiotherapy BRACCO IMAGING S.P.A. (IT) 2007-10-04 US disclosed
US-20070231257-A1 Radiodiagnosis, radiotherapy BRACCO IMAGING S.P.A. (IT) 2007-10-04 US disclosed
US-7226577-B2 Gastrin releasing peptide compounds BRACCO IMAGING, S. P. A. (IT) 2007-06-05 US disclosed
US-7226577-B2 Gastrin releasing peptide compounds BRACCO IMAGING, S. P. A. (IT) 2007-06-05 US disclosed
WO-2007002500-A1 GASTRIN RELEASING PEPTIDE COMPOUNDS BRACCO IMAGING S.P.A. (IT) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130136691-A1 GASTRIN RELEASING PEPTIDE COMPOUNDS GRPR, GIPR, GHRHR TDP1 3331/4885BLM 1481/4885PMP22 2560/4885
US-20080008649-A1 Gastrin Releasing Peptide Compounds GRPR, SSTR5, GIPR TDP1 4470/4885BLM 3914/4885PMP22 4702/4885
US-20070231257-A1 Radiodiagnosis, radiotherapy GRPR, MRGPRX2, MRGPRX1 TDP1 4460/4885BLM 3549/4885PMP22 1827/4885
US-20080247946-A1 Bombesin capable of complexing with metal ions, radionuclides, or optical labels; radiotherapy GRPR, MRGPRX1, BRS3 TDP1 4515/4885BLM 2500/4885PMP22 2794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.